Sasikumar, Pottayil G.
Sudarshan, Naremaddepalli S.
Adurthi, Srinivas
Ramachandra, Raghuveer K.
Samiulla, Dodderi S.
Lakshminarasimhan, Anirudha
Ramanathan, Anuradha
Chandrasekhar, Talapaneni
Dhudashiya, Amit A.
Talapati, Sumalatha R.
Gowda, Nagesh
Palakolanu, Sreenivasulareddy
Mani, Jiju
Srinivasrao, Bandi
Joseph, David
Kumar, Nigam
Nair, Rashmi
Atreya, Hanudatta S.
Gowda, Nagaraj
Ramachandra, Murali http://orcid.org/0000-0003-4039-1491
Article History
Received: 19 August 2020
Accepted: 5 May 2021
First Online: 8 June 2021
Competing interests
: P.G.S., N.S.S., and M.R. are inventors on patent applications related to immune checkpoint inhibitors described in this manuscript (WO2011161699, WO2013132317, WO2015033303 and WO2015033299). All authors except H.S.A. and D.J. are present or previous employees of Aurigene Discovery Technologies Limited, a company that is co-developing CA-170 for cancer therapy.